We evaluated the performance of four visually read pregnancy tests (TestPack Plus hCG Combo, ICON II hCG, SureCell hCG-Serum/Urine and PregnaGen 1-Step) designed to detect increased concentrations of choriogonadotropin (hCG) in either serum or urine samples. The biochemical sensitivities and specificity in both serum and urine samples were similar for each kit. We also evaluated whether these assays could be used for quantitative measurements of serum and urine concentrations of hCG by measuring the time from the end of reagent addition to the appearance of a positive result.
Four Rapid Serum-Urine Combination Assays of Choriogonadotropin (hCG) Compared and Assessed for Their Utility in Quantitative Determinations of hCG
Suha H. Mishalani,1 Judith Seliktar,2 and Glenn D. Braunstein2 '3 We evaluated the performance of four visually read pregnancy tests (TestPack Plus hCG Combo, ICON II hCG, SureCell hCG-Serum/Urine and PregnaGen 1-Step) designed to detect increased concentrations of choriogonadotropin (hCG) in either serum or urine samples. The biochemical sensitivities and specificity in both serum and urine samples were similar for each kit. All kits correctly identified pregnancy serum samples: The TestPack Plus hCG Combo and SureCell hCG-Serum/Urine were 100% specific; the other two kits exhibited a few false-positive results. For urine samples the ICON II hCG test was 100% sensitive, and the other three were 99.5% sensitive, with false-positive urine results occasionally reported by the PregnaGen 1-Step and ICON II hCG tests. Quantitative hCG concentrations could be estimated in pregnancy serum samples, but not urine samples, through determination of the time elapsed from the sample application or addition of the final reagent to the first appearance of a positive result.
Indexing Terms: pregnancy testing/intermethod comparison/variation, source of
Despite the number of commercially available tests for the qualitative measurement of choriogonadotropin (hCG) in serum or urine, relatively few are approved for hCG determination in serum and urine. 4 Because no extensive comparative evaluation among these kits has been reported, we compared the performance of four commercial products with regard to each assay's biochemical and clinical sensitivity and specificity. We also evaluated whether these assays could be used for quantitative measurements of serum and urine concentrations of hCG by measuring the time from the end of reagent addition to the appearance of a positive result.
Materials and Methods
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were collected from 201 pregnant women, 100 postmenopausal women, 100 nonpregnant premenopausal women, and 100 men. Urine samples were collected from 200 pregnant women, 100 poatmenopausal women, 100 nonpregnant premeno- Neg.
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Neg. Neg. sample application or the addition of the final reagent to the first appearance of a positive result. Serial dilutions of pregnancy serum (n = 15) and urine (n = 11) samples were made in normal male serum or urine and were subsequently tested with noting of the time.
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Assay Sensitivity and Specificity
The detection limits in serum and urine samples were similar for each kit, ranging from 15 to 25 lU/L relative to the 3rd IS for hCG (Table 1) ; the specificities were also similar between kits. All recognized the nicked form of hCG, but did not react to the (3- hCG-Serum/Urinewere also 100% specific with respect to 100 nonpregnant women and 100 men, but one serum sample from a nonpregnant premenopausal woman and another from one man were weakly positive with PregnaGen 1-Step (99% specificity).
Neither patient had any conditions known to be associated with positive hCG test results. To confirm the false positivity, we tested both samples with the total hCG RIA and the IMx holo-hCG assay; both were negative: <10 IU/L (2nd IS) and <7.5 lU/L (3rd IS), respectively ( Table 2) . Sera from 100 postmenopausal women showed three false-positive results by ICON II hCG: One patient had metastatic carcinoma to the liver with unknown primary source, the second had appendicitis, and the third had congestive heart failure and was receiving L-thyroxine for hypothyroidism. All three samples were negative by both the total and holohCG immunoassays.
The other three kits were all concordant for the postmenopausal samples, testing negative in all 100 specimens.
Urine samples from 200 pregnant women were all positive by the ICON II hCG test. The remaining three kits had a sensitivity of 99.5% because of one falsenegative result for a sample that measured 7810 lU/L by RIA. To evaluate the cause of this single false-negative pregnant urine sample, we examined 1:1 (by vol) dilutions of another pregnant urine sample (containing 265 lUlL hCG by RIA). One dilution was done with normal male urine and another with the false-negative 
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Vaiues in parentheses are the detectionlimitsreported by the manufacturers.
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Urine Table 2 . False-positIve serum and urine results from patients who were not pregnant.
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heart failure and pancreatic carcinoma ( Table 2 ). The latter patient had immunoreactive hCG-like material, 103 IU/L, in her urine. The material was not hCG; the other three kits failed to detect it, and no immunoreac- 
QuantitativeMeasurements
We timed how long it took after the addition of samples or final reagent for a positive result to appear, using urine sample. The latter dilution yielded a weaker response, suggesting the presence of an inhibitor in the serial dilutions of hCG standards dissolved in serum or false-negative urine sample. The specificity obtained by urine. This generated highly correlated regression testing urine samples from 100 nonpregnant premenocurves between the measured concentrations of hCG (up pausal women and 100 men were 100% (all tested negto 1000 lU/L) vs time (in seconds) for each kit (Fig. 1) . ative) in all four kits. However, of the 100 postmeno-
The effect of freezing and thawing two plasma and two pausal urines tested by ICON II hCG, 7 were falsely positive (pregnant) serum samples on the timed rePre-m., premenopausal women. sponse was studied by assaying the samples when they were fresh and after they were frozen and thawed five times. There was no change in the time for the signal to develop, the appearance of the background, or the signal intensity in any of the four kits. Fifteen serum samples from women in early pregnancy were timed as to the first appearance of a positive result, and the concentration of hCG was determined by using the hCG concentration vs time regression curve for each kit. The corresponding estimated concentration of hCG was compared with the actual concentration measured by lMx by using Pearson's correlation coefficient after logarithmic transformation of the data. Fig. 2 shows significant correlations between the actual and calculated hCG determinations for each kit. The ratios between the calculated hCG and the measured concentrations were between 1 and 2 for three of the kits and <1 for the PregnaGen 1-Step kit (Fig. 2) . We repeated this type of determination with 11 urine samples from pregnant women (Fig. 3) . The correlation coefficients between urine hCG concentrations measured in a total hCG RIA (Fig. 3A) and calculated with the kits ranged from 0.08 (PregnaGen 1-Step) to 0.64 (ICON II hCG), with only the latter achieving statistical significance.
The poor correlation obtained with the urine samples was probably due in part to the presence of intact hCG, 13-core fragment, and possibly other fragments that are detected in urine with the total hCG RIA, whereas only intact (holo) hCG is detected by the kits. Indeed, when we used the IMx assay to measure only the holo-hCG molecule in these samples, the correlation between the measured and the calculated 1ICG concentrations markedly improved for the TestPack Plus hCG Combo and ICON II hCG kits (Fig. 3B) to preclude the use of this method to estimate urine hCG concentrations.
In contrast, serum samples, which showed a statistically significant correlation, contain only miniscule amounts of the p-core fragment (7) and therefore are devoid of such problems. In this study the correlation between total hCG and holo-hCG measured in the IMx assays of pregnancy serum samples was 1.0 (P <0.001), vs 0.56 (not significant) for pregnancy urine samples.
Performance
Characteristics Table 3 outlines the major performance characteristics of the four tests. The time from the initial step of adding the samples to a positive result for samples containing high concentrations of hCG was shortest for the 
Discussion
The results of our studies with purified or partially purified The PregnaGen 1-Step kit had a single false-positive result in the 300 urine samples from nonpregnant subjects.
Rapid hCG serum-urine combination assays are particularly useful for detecting pregnancy in physicians' offices, emergency rooms, and hospitals and before the performance of x-rays or nuclear medicine studies. In several settings, it would be extraordinarily useful to have the ability to utilize these tests to rapidly determine the quantitative concentration of hCG-e.g., in evaluating women thought to have an ectopic pregnancy, as an adjunct to the diagnosis of missed abortion or impending miscarriage, in assisted reproductive technology programs, or in decision-making regarding therapy of patients with gestational trophoblastic disease while they are in the physician's office. When we evaluated the possibility of utilizing these tests for quantifying hCG in serum or urine, we found a strong correlation between the hCG concentration (to 1000 lU/L) and time from sample or reagent addition to the appearance of a positive test result (Fig. 1) . We also found a strong correlation, in serum samples, between the measured hCG in individual samples and the concentrations determined through timing of the assay in the TestPack hCG Combo and ICON II hCG tests; the other two kits showed a statistically significant but weaker correlation (Fig. 2) . Despite the great variability, these tests provide reasonable enough estimates of the actual concen-tration to be useful clinically.
In addition, if serial samples are obtained and diluted in nonpregnant serum, simultaneous assay in the rapid tests with careful timing of the first appearance of a positive result could approximate trends and half-times of hCG disappearance.
We were not able to reach the same conclusion for urine samples, in part because of the presence of the 13-core fragment of hCG in the pregnancy urine samples (8). This fragment is detected in our total hCG RIA but not in any of the kits tested (Table 1) . Using an RIA specific for holo-hCG in the urine, we demonstrated significant correlations between the estimated hCG concentration and the measured concentration with the TestPack hCG Combo and ICON II hCG kits (Fig. 3B) . However, the amount of variability in the ratios of calculated-to-measured hCG concentrations with these two kits and the lack of any significant correlation between the calculated and measured concentrations in the other two kits indicate that other factors present in the urine render the approximation of hCG content through timing of the assay response inadequate for clinical use.
In summary, each of the kits tested performed well in detecting pregnancy in both serum and urine samples. 
